Abstract:Significance Insulin is a target of CD4 T cells in type 1 diabetes in mice and humans. Why the major epitope in the insulin B chain is presented poorly to the diabetogenic CD4 T cells by the disease-associated major histocompatibility class II (MHCII) alleles has been highly debated. Here we present high-resolution mouse and human MHCII structures and T-cell functional data to show that C-terminal modifications of this epitope are required for binding and presentation in the appropriate position in the MHCII binding groove. These results suggest that pancreas-specific posttranslational modifications of this peptide may play a role in the induction of diabetes and explain how the pathogenic T cells escape deletion in the thymus. A polymorphism at β57 in some major histocompatibility complex class II (MHCII) alleles of rodents and humans is associated with a high risk for developing type 1 diabetes (T1D). However, a highly diabetogenic insulin B chain epitope within the B:9–23 peptide is presented poorly by these alleles to a variety of mouse and human CD4 T cells isolated from either nonobese diabetic (NOD) mice or humans with T1D. We have shown for both species that mutations at the C-terminal end of this epitope dramatically improve presentation to these T cells. Here we present the crystal structures of these mutated peptides bound to mouse IAg7 and human HLA-DQ8 that show how the mutations function to improve T-cell activation. In both peptide binding grooves, the mutation of B:22R to E in the peptide changes a highly unfavorable side chain for the p9 pocket to an optimal one that is dependent on the β57 polymorphism, accounting for why these peptides bind much better to these MHCIIs. Furthermore, a second mutation of the adjacent B:21 (E to G) removes a side chain from the surface of the complex that is highly unfavorable for a subset of NOD mouse CD4 cells, thereby greatly enhancing their response to the complex. These results point out the similarities between the mouse and human responses to this B chain epitope in T1D and suggest there may be common posttranslational modifications at the C terminus of the peptide in vivo to create the pathogenic epitopes in both species.

A Single L/D-Substitution at Q4 of the mInsA2-10 Epitope Prevents Type 1 Diabetes in Humanized NOD Mice

A Single L/D-Substitution at Q4 of the mInsA<sub>2-10</sub> Epitope Prevents Type 1 Diabetes in Humanized NOD Mice

An altered CD8 + T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice

A Novel Tolerogenic Antibody Targeting Disulfide-Modified Autoantigen Effectively Prevents Type 1 Diabetes in NOD Mice

C-terminal Modification of the Insulin B:11–23 Peptide Creates Superagonists in Mouse and Human Type 1 Diabetes

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells.

Human insulin as both antigen and protector in type 1 diabetes

Transgenic Insulin (B:9-23) T-Cell Receptor Mice Develop Autoimmune Diabetes Dependent Upon RAG Genotype, H-2g7 Homozygosity, and Insulin 2 Gene Knockout

A mutagenesis study of autoantigen optimization for potential

Cell-surface ZnT8 antibody prevents and reverses autoimmune diabetes in mice

CD4+ T cells reactive to a hybrid peptide from insulin-chromogranin A adopt a distinct effector fate and are pathogenic in autoimmune diabetes

Type 1 diabetes induction in humanized mice.

Protective Response Against Type 1 Diabetes in Nonobese Diabetic Mice after Coimmunization with Insulin and Dna Encoding Proinsulin

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

HLA A*24:02-restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes

HLA-E-restricted Regulatory CD8(+) T Cells Are Involved in Development and Control of Human Autoimmune Type 1 Diabetes.

Regulatory CD4+ T cells redirected against pathogenic CD8+ T cells protect NOD mice from development of autoimmune diabetes

Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.

B Lymphocytes Expressing High Levels of PD-L1 Are Key Regulators of Diabetes Development in Non-Obese Diabetic Mice.

111-OR: Macrophage IPLA2ß-Derived Lipid (idl) Signaling Promote Type 1 Diabetes Development